Navigation Links
Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift
Date:10/28/2008

WASHINGTON, D.C. (October 28, 2008) Scientists at NanoBio Corporation have demonstrated for the first time in humans that a novel topical treatment for cold sores (herpes labialis), NB-001, speeds healing of lesions as effectively as the leading oral systemic drugs but without safety or toxicity concerns.

The new data provide the first proof of principle that a topical agent can attain equivalent efficacy rates to oral systemic drugs, according to the NanoBio scientists. Topical treatments are widely considered inferior to oral systemic treatments because they fail to penetrate to the site of infection with adequate drug levels required to subdue infections.

In the study of 482 patients, NB-001 healed lesions 1.3 days faster than placebo as measured by investigators (P=0.006). Results of the randomized, double-blind, placebo-controlled, phase 2b trial are being presented at the 48th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C.

NB-001 was well tolerated, without safety concerns or adverse events, and was not systemically absorbed. "NB-001 challenges the conventional wisdom that topical therapies are less effective, because NB-001 directly accesses the site of infection in the dermis and epidermis instead of remaining on top of the skin," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "NB-001 employs a physical mode of action to disrupt the outer membranes of pathogens and prompt viral lysis, essentially killing on contact."

The study also suggests that the physical mode of action of NB-001 significantly reduces the likelihood that pathogens will develop resistance to the biocidal effect of the topical lotion.

"These characteristics make NB-001 an ideal candidate for first-line treatment with the potential for widespread use across a broad range of patients," said Mary Flack, M.D., vice president of clinical research at NanoBio and author of the oral presentation.

NanoBio scientists credit the topical lotion's safety and robust anti-infective activity to NB-001's novel technology platform. The lotion is composed of an oil-in-water emulsion and a commonly used antimicrobial surfactant that are mixed at high speeds to nanosize the particles and infuse them with high levels of potential energy. The resulting nanodroplets easily penetrate hair follicles and skin pores to reach the site of infection without damaging skin or mucous membranes. Upon contact with the pathogen, the highly charged particles release their energy to the pathogen's outer membranes, disrupting the viral particle.

"The ability of NB-001 to penetrate skin pores and hair follicles is essential to its activity in the dermis and epidermis, where it surrounds and fuses with herpes simplex virus and disrupts the outer envelope of the pathogen," Flack said. "NB-001 does not compromise tissue integrity, so it is not absorbed into the bloodstream."

Because the herpes simplex virus causes both cold sores and genital herpes, there is a strong potential that NB-001 will also be effective in treating genital lesions, she added.

NanoBio is currently testing its pipeline of topical products against a wide range of skin infections including onychomycosis (nail fungus), tinea capititis (ringworm) and acne.


'/>"/>

Contact: Becky Levine
blevine@medthink.com
919-786-4918
MedThink Communications
Source:Eurekalert

Related medicine news :

1. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
2. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
3. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
4. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
5. Topical treatment for age spots, from Harvard Womens Health Watch
6. Summit VetPharm Introduces New Feline Topicals Vectra(TM) for Cats & Kittens and Vectra(TM) for Cats
7. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
8. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
9. Topical Cream Treats Precancerous Lesions of Vulva
10. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
11. Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... In ... and Clark College Emeritus Professor of Education Gregory A. Smith examines student privacy ... Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . ...
(Date:9/20/2017)... CHARLOTTE, NC (PRWEB) , ... September 20, 2017 ... ... for Transformation and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) ... newly designed presence offers quick and easy access to essential information that offers ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... one of the Best Places to Work in the Research Triangle for 2017. ... Once nominated, a company had to meet a threshold in employee participation--a percentage ...
(Date:9/20/2017)... ... September 20, 2017 , ... Doctors on Liens has added ... network of medical professionals working on a personal injury lien basis. Founded by Dr. ... brings these esteemed doctors’ vast experience with orthopedic injuries to patients in the Inland ...
(Date:9/20/2017)... ... 20, 2017 , ... Mirror Mirror Beauty Boutique is excited ... This Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon will include ... Beauty Boutique is Houston’s largest CoolSculpting provider, holding the prestigious title ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, M.D., ... Professional Member in recognition of his contributions to the ... as a Nephrologist at the practice of Kidney and ... kidney care and hypertension solutions. He has worked in ... of career experience, as well as expertise in kidneys, ...
Breaking Medicine Technology: